Hello. Sign in to personalize your visit. New user? Register now.  
DNA and Cell Biology
Frequent 14-3-3 σ Promoter Methylation in Benign and Malignant Prostate Lesions

To cite this article:
Rui Henrique, Carmen Jerónimo, Mohammad O. Hoque, André L. Carvalho, Jorge Oliveira, Manuel R. Teixeira, Carlos Lopes, David Sidransky. DNA and Cell Biology. April 2005, 24(4): 264-269. doi:10.1089/dna.2005.24.264.

Published in Volume: 24 Issue 4: April 5, 2005

Full Text: • PDF for printing (90.4 KB) • PDF w/ links (140.3 KB)


Rui Henrique
Department of Otolaryngology–Head and Neck Surgery, Head and Neck Cancer Research Division, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Department of Pathology, Portuguese Oncology Institute—Porto, Porto, Portugal.
Carmen Jerónimo, Ph.D.
Department of Otolaryngology–Head and Neck Surgery, Head and Neck Cancer Research Division, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Department of Genetics, Portuguese Oncology Institute—Porto, Porto, Portugal.
Fernando Pessoa University School of Health Sciences, Porto, Portugal.
Mohammad O. Hoque
Department of Otolaryngology–Head and Neck Surgery, Head and Neck Cancer Research Division, Johns Hopkins University School of Medicine, Baltimore, Maryland.
André L. Carvalho
Department of Otolaryngology–Head and Neck Surgery, Head and Neck Cancer Research Division, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Jorge Oliveira
Department of Urology, Portuguese Oncology Institute—Porto, Porto, Portugal.
Manuel R. Teixeira
Department of Genetics, Portuguese Oncology Institute—Porto, Porto, Portugal.
Carlos Lopes
Department of Pathology, Portuguese Oncology Institute—Porto, Porto, Portugal.
David Sidransky
Department of Otolaryngology–Head and Neck Surgery, Head and Neck Cancer Research Division, Johns Hopkins University School of Medicine, Baltimore, Maryland.

14-3-3σ is a putative tumor suppressor gene involved in cell cycle regulation and apoptosis following DNA damage. 14-3-3σ loss of expression has been reported is several human cancers, including prostate adenocarcinoma and precursor lesions, and promoter hypermethylation has been proposed as the mechanism underlying gene silencing. Here, we investigate the frequency and extent of 14-3-3σpromoter methylation in benign and cancerous prostate tissues. We examined tumor tissue from 121 patients with prostate carcinoma (PCa), 39 paired high-grade prostatic intraepithelial neoplasias (HGPIN), 29 patients with benign prostate hyperplasia (BPH), as well as four prostate cancer cell lines using quantitative methylation-specific PCR (QMSP). The percentage of methylated alleles (PMA) was calculated and correlated with clinical and pathological parameters. RT-PCR was performed in the cell lines to assess 14-3-3σ mRNA expression. PCa, HGPIN, BPH, and cancer cell lines showed ubiquitous 14-3-3σpromoter methylation. However, the PMA of HGPIN was significantly lower than that of PCa or BPH (P < 0.0001), while PCa and BPH did not significantly differ. The PMA did not correlate with any clinicopathological parameter. All prostate cancer cell lines expressed 14-3-3σmRNA. 14-3-3σpromoter methylation is a frequent event in prostate tissues and cancer cell lines. Furthermore, there is a progressive accumulation of neoplastic cells with 14-3-3σmethylated alleles from HGPIN to PCa, suggesting a role for this epigenetic event in prostate carcinogenesis. However, other mechanisms besides promoter methylation might be required for effective 14-3-3σdownregulation.

Free first page

This paper was cited by:

Isoform-specific expression and characterization of 14-3-3 proteins in human glioma tissues discovered by stable isotope labeling with amino acids in cell culture-based proteomic analysis
Shufang Liang, Guobo Shen, Qingping Liu, Yuhuan Xu, Liangxue Zhou, Shiyin Xiao, Zhizhong Xu, Fengming Gong, Chao You, Yuquan Wei
PROTEOMICS - CLINICAL APPLICATIONS. Jul 2009, Vol. 3, No. 6: 743-753
CrossRef
Molecular Alterations in Prostate Cancer as Diagnostic, Prognostic, and Therapeutic Targets
Bora Gurel, Tsuyoshi Iwata, Cheryl M. Koh, Srinivasan Yegnasubramanian, William G. Nelson, Angelo M. De Marzo
Advances in Anatomic Pathology. Dec 2008, Vol. 15, No. 6: 319-331
CrossRef
Epigenetic silencing contributes to the loss of BRMS1 expression in breast cancer
Brandon J. Metge, Andra R. Frost, Judy A. King, Donna Lynn Dyess, Danny R. Welch, Rajeev S. Samant, Lalita A. Shevde
Clinical & Experimental Metastasis. Dec 2008, Vol. 25, No. 7: 753-763
CrossRef
Gene expression and methylation status of 14‐3‐3σ in human renal carcinoma tissues
Shufang Liang, Yuhuan Xu, Guobo Shen, Xinyu Zhao, Jin Zhou, Xingbin Li, Fengming Gong, Bo Ling, Li Fang, Canhua Huang, Yuquan Wei
IUBMB Life. Sep 2008, Vol. 60, No. 8: 534-540
CrossRef
Genetic changes and DNA damage responses in the prostate
Taija M. Kiviharju-af Hällström, Marikki Laiho
The Prostate. Jul 2008, Vol. 68, No. 8: 902-918
CrossRef
Quantitative hypermethylation of a small panel of genes augments the diagnostic accuracy in fine-needle aspirate washings of breast lesions
Carmen Jeronimo, Paula Monteiro, Rui Henrique, Mário Dinis-Ribeiro, Isabel Costa, Vera L. Costa, Luísa Filipe, André L. Carvalho, Mohammad O. Hoque, Irene Pais, Conceição Leal, Manuel R. Teixeira, David Sidransky
Breast Cancer Research and Treatment. Jun 2008, Vol. 109, No. 1: 27-34
CrossRef
Relationship between the berrant hypermethylation profile of 14-3-3 sigma and its reduced transcription levels in Chinese women sporadic breast carcinogenesis
Zuojun Wang, Jing Feng, Jun Lu, Yuping Wang, Fei Xie, Youli Zhou, Jicai Zhang, Wenbin Li
The Chinese-German Journal of Clinical Oncology. Nov 2007, Vol. 6, No. 5: 479-483
CrossRef
Promoter hypermethylation of GSTP1, AR, and 14-3-3σ in serum of prostate cancer patients and its clinical relevance
Jochen Reibenwein, Dietmar Pils, Peter Horak, Birgit Tomicek, Gregor Goldner, Nina Worel, Katarzyna Elandt, Michael Krainer
The Prostate. Apr 2007, Vol. 67, No. 4: 427-432
CrossRef
14-3-3 proteins: do they have a role in human cancer?
Jesse D Martinez
Future Oncology. Nov 2005, Vol. 1, No. 5: 631-633
CrossRef
All articles
Previous Next